Insulin

In patients with basal insulin-treated type 2 diabetes, sotagliflozin was associated with greater time in range compared with placebo at 18 weeks, researchers reported at the European Association for the Study of Diabetes Annual Meeting.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

A novel once-weekly basal insulin conferred noninferior HbA1c reductions compared with daily insulins for insulin-naive adults with type 2 diabetes and those who switched from daily injections, according to topline results from two trials.

Adults with prediabetes and overweight or obesity who take the GIP/GLP-1 dual agonist tirzepatide once weekly may be 94% less likely to develop type 2 diabetes, according to results from the SURMOUNT-1 study.

States that approved caps to limit out-of-pocket costs for insulin did not have increased uptake in insulin use among people with diabetes and commercial insurance, according to findings published in Health Affairs.

Researchers purchased prefilled semaglutide pens from six online vendors, of which three were nondelivery scams, according to findings from a research letter published in JAMA Network Open.

A multifaceted intervention implemented at a U.S. hospital reduced insulin pen waste by 18.3% in inpatient adult areas, according to a presenter at the Association of Diabetes Care and Education Specialists annual meeting.